Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women.

Yu Y, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, Lorentzen B, Clausen T, Garg SK, Menard MK, Hammad SM, Scardo JC, Stanley JR, Dashti A, May K, Lu K, Aston CE, Wang JJ, Zhang SX, Ma JX, Lyons TJ.

Diabetologia. 2009 Jan;52(1):160-8. doi: 10.1007/s00125-008-1182-x. Epub 2008 Nov 5.

PMID:
18985316
2.

Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.

Govender N, Naicker T, Rajakumar A, Moodley J.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):100-5. doi: 10.1016/j.ejogrb.2013.05.021. Epub 2013 Jun 24.

PMID:
23806447
3.

Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.

Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E; EBM CONNECT Collaboration.

BJOG. 2012 Jun;119(7):778-87. doi: 10.1111/j.1471-0528.2012.03311.x. Epub 2012 Mar 20. Review.

4.

The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes.

Cohen AL, Wenger JB, James-Todd T, Lamparello BM, Halprin E, Serdy S, Fan S, Horowitz GL, Lim KH, Rana S, Takoudes TC, Wyckoff JA, Thadhani R, Karumanchi SA, Brown FM.

Hypertens Pregnancy. 2014 Feb;33(1):81-92. doi: 10.3109/10641955.2013.837175. Epub 2013 Dec 19.

5.

Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.

Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, Petri M, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Merrill JT, Stephenson MD, Gao Q, Karumanchi SA, Salmon JE.

Am J Obstet Gynecol. 2016 Jan;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066. Epub 2015 Sep 29.

6.

Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.

Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M.

Hypertens Pregnancy. 2009 Feb;28(1):95-108. doi: 10.1080/10641950802419895.

PMID:
19165674
7.

Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.

De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R.

Acta Obstet Gynecol Scand. 2008;87(8):837-42. doi: 10.1080/00016340802253759.

PMID:
18607829
8.

Gestational angiogenic biomarker patterns in high risk preeclampsia groups.

Maynard SE, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, Moore Simas TA.

Am J Obstet Gynecol. 2013 Jul;209(1):53.e1-9. doi: 10.1016/j.ajog.2013.03.017. Epub 2013 Mar 18.

PMID:
23517919
9.

The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.

Aggarwal PK, Chandel N, Jain V, Jha V.

J Hum Hypertens. 2012 Apr;26(4):236-41. doi: 10.1038/jhh.2011.29. Epub 2011 Mar 31.

PMID:
21451568
10.

Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.

Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network.

PLoS One. 2010 Oct 11;5(10):e13263. doi: 10.1371/journal.pone.0013263.

11.

Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?

Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Sciscione A, Tolosa JE, Saade G, Sorokin Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.

BJOG. 2013 Sep;120(10):1183-91. doi: 10.1111/1471-0528.12128. Epub 2013 Jan 18.

12.

Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.

Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, Dong Z, Than NG, Yeo L, Hernandez-Andrade E, Conde-Agudelo A, Hassan SS.

Am J Obstet Gynecol. 2013 Apr;208(4):287.e1-287.e15. doi: 10.1016/j.ajog.2013.01.016. Epub 2013 Jan 17.

13.

Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.

Moore Simas TA, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, Maynard SE.

J Matern Fetal Neonatal Med. 2014 Jul;27(10):1038-48. doi: 10.3109/14767058.2013.847415. Epub 2013 Oct 29.

PMID:
24066977
14.

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group.

N Engl J Med. 2006 Sep 7;355(10):992-1005. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.

15.

Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ.

Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Epub 2010 Jul 19. Erratum in: Circulation. 2011 Sep 13;124(11):e302.

16.

Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.

Rana S, Cerdeira AS, Wenger J, Salahuddin S, Lim KH, Ralston SJ, Thadhani RI, Karumanchi SA.

PLoS One. 2012;7(10):e48259. doi: 10.1371/journal.pone.0048259. Epub 2012 Oct 26.

17.

The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.

Buhimschi CS, Baumbusch MA, Dulay AT, Lee S, Wehrum M, Zhao G, Bahtiyar MO, Pettker CM, Ali UA, Funai EF, Buhimschi IA.

BJOG. 2010 Feb;117(3):321-30. doi: 10.1111/j.1471-0528.2009.02434.x. Epub 2009 Nov 26.

18.

Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study.

Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, Simpson NA, North RA; SCOPE consortium.

BJOG. 2013 Sep;120(10):1215-23. doi: 10.1111/1471-0528.12195. Epub 2013 Mar 21.

19.

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.

Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS.

J Matern Fetal Neonatal Med. 2008 May;21(5):279-87. doi: 10.1080/14767050802034545.

20.

Comparison of angiogenic and anti-angiogenic factors in maternal and umbilical cord blood in early- and late-onset pre-eclampsia.

Sezer SD, Küçük M, Yenisey C, Yüksel H, Odabaşı AR, Türkmen MK, Çetinkaya Çakmak B, Ömürlü IK.

Gynecol Endocrinol. 2012 Aug;28(8):628-32. doi: 10.3109/09513590.2011.650759. Epub 2012 Mar 20.

PMID:
22429154

Supplemental Content

Support Center